Abstract 176P
Background
In China, surgical resection and ablation are widely used to treat HCC; however, relapse rates are high for patients with residual elevated AFP 2 months post-treament. LEN has been shown to reduce AFP levels in patients with advanced HCC. We therefore investigated the efficacy of LEN for preventing recurrence in patients with HCC and elevated AFP after surgery or ablation.
Methods
This single-center, retrospective study, conducted between Nov 2018 and Jan 2020, included medical records from 84 patients with HCC who achieved complete radiologic response following resection or radiofrequency ablation, had high residual AFP (>20 ng/mL) 8 weeks post-surgery and received LEN according to local labelling (n=23), adjuvant transarterial chemoembolization (TACE; n=25) or no treatment (Control group, n=36). A further group of patients with HCC R0 resection (AFP negative post-surgery) was also included (n=22). AFP response was defined as >20% reduction in AFP ≤8 weeks from initiation of LEN. Recurrence free survival (RFS) was calculated from initiation of treatment (LEN and TACE groups) or the date of surgery (Control and R0 groups) until first confirmed local, regional or distant tumor recurrence.
Results
Median follow-up in all patients was 11.2 months. Patient baseline characteristics were similar between groups, except for baseline BCLC stage. Among patients receiving LEN, 61% (14/23) achieved an AFP response. The rate of 1-year RFS was higher for patients in the LEN group who achieved an AFP response (71.4% [10/14]) compared with the TACE (36.0% [9/25]) and Control (50.0% [18/36]) groups. Median RFS had not been reached in the LEN, TACE, and R0 groups. At data cutoff, 9 (64.3%) patients receiving LEN who achieved an AFP response were recurrence free, and follow-up is on-going.
Conclusions
LEN led to an AFP response in 61% of patients with HCC and residual elevated AFP post surgery/ablation, and this was associated with a high 1-year RFS. Therefore, AFP response may provide a biomarker to predict response to LEN in this setting and further investigation in prospective trials is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session